about header
Press Releases
Print Text Size
  • 12/3/14 8:00 am EST
    CAMBRIDGE, Mass.--

    Genzyme, a Sanofi company, today announced that the first U.S. patients have initiated treatment with Lemtrada® (alemtuzumab) in the commercial setting following its November 14th FDA approval for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

    more...
  • 11/21/14 7:15 am EST
    CAMBRIDGE, Mass.--

    Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Cerdelga® (eliglustat) capsules, an oral treatment for certain adults living with Gaucher disease type 1.

    more...
  • 11/18/14 3:45 pm EST
    CAMBRIDGE, Mass. & CARLSBAD, Calif.--

    Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that new two-year data from a phase 3 long-term extension study of KYNAMRO® (mipomersen sodium) injection was presented at a scientific session at the annual American Heart Association meeting in Chicago, IL. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events (MACE) compared to two years prior to therapy.

    more...
  • 11/14/14 9:00 pm EST
    CAMBRIDGE, Mass.--

    Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved LemtradaTM (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

    more...
  • 11/4/14 6:00 am EST
    CAMBRIDGE, Mass.--

    Genzyme, a Sanofi company, announced today enrollment of the first patient in a multicenter Phase II clinical trial to evaluate Genzyme’s investigational infusion therapy vatelizumab in patients with relapsing remitting multiple sclerosis (RRMS). The trial, called EMPIRE, is designed to assess the efficacy of vatelizumab vs. placebo in RRMS patients. The safety, tolerability and pharmacokinetics of vatelizumab will also be assessed.

    more...
  • 10/20/14 10:35 am EDT
    CAMBRIDGE, Mass.--

    Genzyme, a Sanofi company, announced today that the Food and Drug Administration (FDA) has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio® (teriflunomide) in the product’s U.S. label.

    more...
  • 10/13/14 8:07 am EDT
    Cambridge, MA--

    Genzyme, a Sanofi company, announced today that it is collaborating with television and film actress Madeleine Stowe to launch “Lights, Camera, Take Action on MS,” a campaign intended to educate and empower people living with multiple sclerosis (MS) to take action to help manage their disease. Madeleine, who was a care partner to her late father who had MS, will be touring the country to share her personal connection to the disease through a series of in-person and online events.

    more...
  • 10/1/14 8:00 am EDT
    CAMBRIDGE, Mass.--

    Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the recipients of the 2014 Genzyme Patient Advocacy Leadership (PAL) Awards. This global grant program supports innovative projects by non-profit organizations in disease awareness and education, community mobilization, non-profit development and good governance activities, patient care and support programs.

    more...
  • 9/24/14 8:00 am EDT
    CAMBRIDGE, Mass.--

    Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the establishment of a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene therapy for the treatment of a rare genetic disease that causes childhood blindness. Leber congenital amaurosis type 1 (LCA-1) is usually diagnosed in children who are less than a year old, and patients remain severely visually impaired for the rest of their lives.

    more...
  • 9/11/14 1:00 am EDT
    CAMBRIDGE, Mass.--

    Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today positive interim results from the second year of the extension study of Lemtrada (alemtuzumab) for multiple sclerosis.

    more...
Contact Us
 

Media Resources

Tweets

Social Media

Business Wire NewsHQ℠
infoBox